Six of Lincoln’s former staffers currently lobby for interests invested in influencing carbon capping legislation. These interests include oil & gas trade groups, agriculutural companies, the airplane industry and biofuel and bioenergy firms. As chair of the Senate Committee on Agriculture, Lincoln holds a powerful position to influence carbon capping legislation and she has made no secret of her desire to block the legislation.

(For a full visualization of Sen. Blanche Lincoln’s former staffers lobbying for the energy and climate industries click here or the image to the right.)

The most influential of Lincoln’s former staffers is Kelly Bingel, a lobbyist for Mehlman Vogel Castagnetti. Bingel is a former chief of staff to Lincoln and has been called “Sen. Lincoln’s alter ego.” Bingel’s clients include two incredibly powerful organizations opposed to carbon capping: the American Petroleum Institute (API), the lead trade group for the oil industry, and Koch Industries, one of the largest oil manufacturing, trading and investment companies in the country. David Koch, one of the two owners of Koch Industries, is a big contributor to conservative movement organizations and is an outspoken opponent of cap and trade legislation. Koch has invested millions in various conservative organizations that have led lobbying and grassroots stimulation efforts to get people to advocate to their lawmakers to oppose cap and trade legislation. API spent $7.32 million on lobbying last year, almost double what it spent in 2008. API states that any carbon capping legislation or regulations will cost the industry jobs and increase taxes.

According to the Center for Responsive Politics, Lincoln is currently the number one recipient of campaign contributions from the oil and gas industry from 2005 to 2010. She has received, through her campaign committee and her leadership political action committee (PAC),$309,500 from the industry.

Another former staffer to Lincoln, Ben Noble, lobbies for organizations opposed to carbon capping efforts including a variety of agricultural interests. Agricultural companies and trade groups have a major stake in cap and trade legislation as it moves through Congress. According to the EPA, agriculture accounts for 6 percent of all U.S. greenhouse gas emissions. The industry is seeking to avoid carbon capping regulation in cap and trade legislation or through EPA regulation.

One of Noble’s clients, the USA Rice Federation, opposes cap and trade legislation and recently praised Lincoln for her stance against the legislation, “We applaud Chairman Lincoln for putting the American economy and jobs first in this debate. While there are a number of questions surrounding the issue of climate change, there is absolutely no question about the severe impact that pending legislation and regulation would have on our economy and jobs.”

Lincoln is the top recipient of campaign contributions from a variety of agricultural industries including agricultural services, crop producers, food processors and meat processors and plants. Since 2005, Lincoln has received $789,372 from the agribusiness sector.

Both Bingel and Noble also represent organizations generally supportive of cap and trade legislation, so long as it contains language that allows them to maximize their profits under the new system. Bingel represents the electrical utility trade group the Electric Edison Institute (EEI). EEI, which includes members who have received specific benefits in the House-passed cap and trade legislation, sees the legislation as an openning into new markets with high potential to increase their share of energy distribution.

Noble represents the massive bio-tech, agribusiness firm Monsanto. Monsanto seeks to gain profits from a cap and trade system by getting farms and agribusiness to switch to a “no-till” method of farming. The “no-till” method would require farmers to purchase herbicides and seeds made by Monsanto. The lobbying effort by Monsanto is detailed in Tom Philpott’s explanation at Grist.

Last week, Lincoln released her first campaign advertisement in the uphill battle to retain her Senate seat. The ad touts her continued opposition to the passage of cap and trade legislation. This continues her statement from last year that cap and trade is a “complete non-starter.”

(Revision: Todd Wooten no longer lobbies for Enerkem. He is currently employed by Duke University.)

Over the following months, pharmaceutical industry lobbyists and executives met with top White House aides dozens of times to hammer out a deal that would secure industry support for the administration’s health care reform agenda in exchange for the White House abandoning key elements of the president’s promises to reform the pharmaceutical industry. They flooded Congress with campaign contributions, and hired dozens of former Capitol Hill insiders to push their case. How they did it—pieced together from news accounts, disclosure forms including lobbying reports and Federal Election Commission records, White House visitor logs and the schedule Sen. Max Baucus releases voluntarily—is a testament to how ingrained the grip of special interests remains in Washington.

In the 2008 campaign, Obama declared his intention to include all stakeholders as he sought to reform the nation’s health care system, but also supported key Democratic health reform policies. Among these were several that targeted the pharmaceutical industry: Allowing re-importation of drugs from first world countries with lower drug prices and providing Medicare with negotiating authority over prescription drug prices in the recently enacted Part D program. These weren’t just promises, Obama had already voted for both of them as a senator in 2007. (Roll Call Vote 132 and Roll Call Vote 150.)

Set to carry out this agenda were two Capitol Hill veterans, schooled in the monied Washington culture, chief of staff Rahm Emanuel and deputy chief of staff Jim Messina. Emanuel was a former fundraiser, Clinton administration official, investment banker and member of the Democratic leadership in Congress. Messina was the former campaign manager and chief of staff to the powerful Senate Finance Committee chairman Max Baucus. Both were known for their unparalleled legislative abilities.

Because of Obama’s decision to develop a plan operating through the legislative process, members of Congress also played key roles. Early on, the pharmaceutical companies were told to deal directly with Senate Finance Committee chairman Max Baucus. Baucus would be the vehicle for the deal worked out behind the scenes by the White House and PhRMA.

Central to this effort was PhRMA president, CEO and top lobbyist Billy Tauzin, a longtime Democratic member of Congress who switched party affiliations after Republicans gained control of Congress in 1994. By switching parties Tauzin was able to maintain his influence and even rose to be Chairman of the House Committee on Energy & Commerce. Tauzin became the poster child of Washington’s mercenary culture. He crafted a bill to provide prescription drug access to Medicare recipients, one that provided major concessions to the pharmaceutical industry. Medicare would not be able to negotiate for lower prescription drug costs and reimportation of drugs from first world countries would not be allowed. A few months after the bill passed, Tauzin announced that he was retiring from Congress and would be taking a job helming PhRMA for a salary of $2 million.

Tauzin’s job change became fodder for a campaign ad that then presidential candidate Barack Obama ran in the spring of 2008 simply titled “Billy.” It featured the candidate, sleeves rolled up, talking to a salon of gasping Americans about the ways of Washington. “The pharmaceutical industry wrote into the prescription drug plan that Medicare could not negotiate with drug companies. And you know what, the chairman of the committee, who pushed the law through, went to work for the pharmaceutical industry making $2 million a year.” The screen fades to black to inform the viewer that, “Barack Obama is the only candidate who refuses Washington lobbyist money,” while the candidate continues his lecture, “Imagine that. That’s an example of the same old game playing in Washington. You know, I don’t want to learn how to play the game better, I want to put an end to the game playing.”

Aiding PhRMA in their outreach to Congress would be a squadron of lobbyists to push their health care reform priorities. Over the course of 2009, the drug industry trade group spent over $28 million on in house and hired lobbyists. Aside from PhRMA’s massive in-house lobbying operation, the trade group hired 48 outside lobbying firms. The total number of lobbyists working for PhRMA in 2009 reached 165. Some 137 of those 165 lobbyists representing PhRMA were former employees of either the legislative or executive branches. Of these dozens were former congressional staffers including two former chiefs of staff to Max Baucus.

According to data compiled by the Center for Responsive Politics, drug makers contributed huge sums to congressional campaign committees during the same period—from January to the end of October (4th quarter numbers are still being totaled), industry political action committees, employees and their family members flooded lawmakers with over $8 million. Those contributions tilted heavily to Democrats over Republicans by a 57 to 42 percent margin—the first time in any election cycle going back to 1990, the first year that the Center for Responsive Politics began tracking industry giving, that Democrats were so favored. Given their majorities on Capitol Hill, and the new President’s intention to reform America’s health care system, the new tilt was perhaps not surprising.

***

On March 5, the White House held a meeting with major health care industry leaders to try to bring them to the table and see what could be done to gain their support. In attendance were Billy Tauzin, president, CEO and top lobbyist for PhRMA, Pfizer CEO Jeff Kindler, America’s Health Care Plans (AHIP) Chairman Karen Ignani, Tom Donohue of the Chamber of Commerce and Robert Wood Johnson Foundations’ Risa Lavizzo-Mourey. A day before the White House meeting Tauzin appeared on CNBC touting health care reform and promising to work closely with the Obama administration. In the interview he touted it as an “optimistic plan”, acknowledging that the industry did have a few problems but was glad to have a chance to discuss these. Some were caught dumb-founded by this apparent change of heart on behalf of an industry long adverse to health care reforms.

On April 15, Jim Messina and Jon Selib, chief of staff to Senate Finance Committee chairman Max Baucus, convened a meeting at the headquarters of the Democratic Senatorial Campaign Committee (DSCC) with leaders of organized labor and health care groups, including PhRMA. At the meeting, the groups decided to form two nonprofit entities to promote reform efforts, Healthy Economy Now and Americans for Stable Quality Care, that would be almost entirely funded by PhRMA. The two groups spent $24 million on their advertising campaigns; the contract to produce and place ads went to White House Senior Advisor David Axelrod’s former firm, AKPD, which owed Axelrod $2 million.

In the next month, CEO’s from pharmaceutical companies would meet with Baucus and administration officials at least four times. These talks preceded a major public event at the White House, one critical to its strategy to promote health care reform. On May 11, PhRMA and other trade industry groups pledged cost cutting measures to the White House that would save, they claimed, upwards of $2 trillion over the next decade. President Obama announced the deal in the State Dining Room, flanked by leaders of the various trade groups; the administration followed up with a media blitz in the press and on the White House Web site.

The next day, Healthy Economy Now’s PhRMA funded ad campaign ran their first advertisement in support of the health care reform process calling for the government to finally “fix” the nation’s health care cost problems. While many elements of the $2 trillion cost cutting pledge fell apart, the drug industry remained committed to the process in the hopes that they could ultimately win out and defeat the provisions they most feared in closed-door meetings with the White House.

The first occurred on June 2. White House visitor logs show PhRMA’s top executives, including Tauzin, and industry CEOs met with Sarah Fenn from the White House Office of Health Care Reform. On the same day, the publicly available schedule of Senator Max Baucus shows Tauzin and the same industry CEOs met the Senate Finance Committee chairman. What ultimately resulted from these coordinated meetings would be revealed by Baucus on June 20.

In a press release featuring a statement by Tauzin, Baucus revealed that the pharmaceutical industry had accepted $80 billion in cost cutting measures to be included in the Senate Finance Committee version of the bill. According to news reports, Baucus initially proposed $100 billion in cost cutting measures, but the executives and lobbyists meeting on June 2 were able to win the lower figure.

The terms of the initial cost-cutting deal included $30 billion go directly towards closing the “donut hole” in Medicare prescription drug coverage.  The “donut hole” is a term for the gap in coverage that occurs within the Medicare prescription drug coverage. For those purchasing prescription drugs through the Medicare program coverage cuts off at $2,700 spent and does not pick back up again until $6,154 is spent by the participant. The amount proposed in the deal, 50 percent coverage for drugs within the coverage gap, however, would not completely close the “donut hole.”

In Baucus’ press release, Tauzin is quoted as saying, “This is a once-in-a-lifetime opportunity and, working together, we can make this hope for a better tomorrow a reality today.” This “once-in-a-lifetime” opportunity also extended to the pharmaceutical industry’s ability to blunt the long-term Democratic agenda of lowering prescription drug prices through Medicare negotiations, re-importation and quicker release of generics onto the market. After making such a grand statement of support through cost cutting proposals it was time for the pharmaceutical industry to finally force the White House and Democrats to take certain chips off the table.

Baucus proceeded with a plan to convene a bipartisan group in an effort to craft the bill desired by the White House. These participants included Democrats Kent Conrad and Jeff Bingaman and Republicans Chuck Grassley, Mike Enzi and Olympia Snowe. Baucus’ decision and the need to solidify deals with groups like the pharmaceutical industry – which were reliant on Baucus producing a bill – slowed down the legislative process making it impossible for Congress to meet the White House’s announced August recess deadline for passing health care reform.

Soon after, PhRMA’s big guns and industry lobbyists paid the White House another visit on July 7 and this time met with Rahm Emanuel and Jim Messina (Baucus’ chief of staff Jon Selib is also listed in White House visitor logs for this meeting). In August, The Huffington Post’s Ryan Grim reported on an internal memo that was drafted at that meeting that outlined the policies that would not be allowed into any final version of health care reform. These included Medicare prescription drug negotiations, drug re-importation, and the lowering of prices for drugs available through Medicare Part D and Part B. The deal would be $80 billion in cost cutting and absolutely no more.

***

While the $80 billion deal was cut with Baucus’ committee, other congressional committees continued to mark-up their own versions of health care reform without the knowledge that the White House was relying on Baucus to produce the final product. In the House of Representatives, the House Energy & Commerce Committee leveled a direct threat to the $80 billion deal. Energy & Commerce Chair Henry Waxman sought to include all of the provisions that PhRMA had gotten the White House and Baucus to cut out of the reform bill. These included drug reimportation, Medicare negotiating power and speedier release of generics to the market. According to previous analysis of the measures proposed by the committee, these measures would have totaled hundreds of billions in cost cuts, far exceeding the $80 billion cap agreed to by the White House, Baucus and PhRMA.

The cost cutting measures passed in the Energy & Commerce bill spooked the board of PhRMA, which included all of the CEOs involved in the deal-cutting meetings with the White House and Baucus. The board pressured Tauzin to go public with the deal to ensure that the White House would recognize it and not renege. On August 4, the Los Angeles Times, in an exclusive report, featured quotes from Tauzin claiming that a deal between the White House and PhRMA existed and that, as Tauzin put it, “The White House blessed it.” Tom Hamburger wrote in the article, “For his part, Tauzin said he had not only received the White House pledge to forswear Medicare drug price bargaining, but also a separate promise not to pursue another proposal Obama supported during the campaign: importing cheaper drugs from Canada or Europe.”

The White House’s Jim Messina later confirmed Tauzin’s claim, stating, “The president encouraged this approach … He wanted to bring all the parties to the table to discuss health insurance reform.”

Democratic lawmakers were furious. Rep. Raul Grijalva, chairman of the Progressive Caucus, asked, “Are industry groups going to be the ones at the table who get the first big piece of the pie and we just fight over the crust?”

***

On September 7, Baucus’ bill made a private circulation on the Hill; pharmaceutical industry cost-cutting did not exceed $80 billion. Five days later, the New York Times reported that PhRMA planned to spend up to $150 million in an advertising blitz in support of Baucus’ bill. The Times noted that the ad spending “…would be a follow-up to the deal that drug makers struck in June with Mr. Baucus and the White House.” On September 16, Baucus released the full text of his legislation to the public.

The White House, PhRMA and Baucus still had to fight a few battles to keep the deal intact. The key amendment targeting the PhRMA deal in committee mark-up came from Sen. Bill Nelson from Florida, which has one of the largest Medicare participant populations in the nation. The pull of constituent needs clearly put Bill Nelson into a position to push for further cost cutting in Medicare prescription drug pricing. His target: closing the “donut hole” completely.

Nelson claimed that his amendment would generate $106 billion in revenue, or from PhRMA’s perspective increase their cost-cutting to $186 billion.  That would be unacceptable to PhRMA, to Baucus, to the White House and to the pharmaceutical industry who had made the deal. Other Senate Democrats, Tom Carper and Robert Menendez voted with Republicans and Baucus on the committee to defeat the amendment.  It is little surprise the Carper’s Delaware is home to AstraZeneca and Menendez’ New Jersey is home to Merck and Bristol-Myers-Squibb, all of which lobbied for the $80 billion cap.

Senate Majority Leader Harry Reid introduced the final bill, with the cap in place, on November 19. Debate began on Dec. 3, and with it come one more attempt by members to change the terms of the deal. Senator Byron Dorgan introduced an amendment that would allow for drug re-importation, but as the date for voting drew near, the Federal Drug Administration (FDA) released a letter objecting to the proposal that echoed pharmaceutical industry talking points: “…as currently written, the resulting structure would be logistically challenging to implement and resource intensive. In addition, there are significant safety concerns.” Dorgan’s amendment was defeated with numerous Democrats previously in support of reimportation switching to “no” votes.

On Christmas Eve, the bill passed the Senate with the PhRMA deal fully intact.

***

New Year’s Eve passed with no further action on health care reform. Public opinion regarding the health care reform bill had been slipping throughout 2009. It reached a fulcrum in the special election to replace the deceased senator Ted Kennedy in Massachusetts on January 19, 2010. Newly minted senator Scott Brown campaigned that he would be the senator to provide Republicans with the votes to filibuster the final health care reform bill. Democrats ran for cover. Despite having the largest majorities of any party since the 1970s, Democrats put the brakes on their agenda, particularly health care reform.

In the end, the pharmaceutical industry’s support for health care reform would be left up in the air. After spending $100 million in advertising in support of legislation that Tauzin and key executives hoped would be a windfall for the pharmaceutical industry, the legislative process had flat-lined. In February, the board of PhRMA, split over the deal cut by Tauzin, pushed Tauzin to resign his post.

In an interview with Diane Sawyer, President Obama owed up to failures in the process of passing health care reform, “[T]he health care debate as it unfolded legitimately raised concerns not just among my opponents, but also amongst supporters that we just don’t know what’s going on … And it’s an ugly process and it looks like there are a bunch of back room deals.”

Today, there are over 13,000 registered lobbyists working in Washington to influence our elected officials and government employees. These 13,000-plus lobbyists spent $2.5 billion on lobbying in the first three quarters of last year (fourth quarter totals are still being tallied). All of this monied influence and we have no idea who they meet with or what they discuss. Sunlight has called for the disclosure of lobbyist contacts for quite some time now. It’s both heartening and surprising to see the President call for the same thing.

Why should lobbyists disclose their contacts to the public?

President Obama explained it very well in his State of the Union last night, “We face a deficit of trust – deep and corrosive doubts about how Washington works that have been growing for years.” These “deep and corrosive doubts” stem, not only from fears of quid pro quo deals struck behind closed doors, but from the belief that there is associational bias in the lobbyist-lawmaker relationship. In a legal essay on lobbying disclosure, Anita Krishnkumar, a law professor at St. John’s University, writes, “…[T]he public perceives that lobbyists receive special face time with elected officials. Irrespective of where that face time occurs — in scheduled meetings, on a train ride, over a game of power, or on the golf course — it creates opportunities for lobbyists to persuade elected officials of their clients’ positions, opportunities that ordinary citizens do not have. In other words, the public’s concern is not just that elected officials will engage in blatant vote-selling to lobbyists, but, more subtly, that they will be partial to the causes of lobbyists’ clients because they spend a lot of time in lobbyists’ company.”

The fears that people have about the relationship between lawmakers and lobbyists can begin to be reduced by the simple disclosure of lobbyist contacts. This disclosure would allow us all to see lobbyists requesting earmarks, writing bills and distributing information. We’d also be able to track lobbyist meetings in the run-up to congressional hearings and floor votes. This would allow for the full story of the legislative process to be put into the public record.

There is no doubt that lobbying is protected by the First Amendment right to petition the government. The massive growth in the lobbying sector, however, has raised serious concerns about policy capture by monied interest groups. It’s time that Congress enact real lobbying reform by requiring the disclosure of lobbying contacts. In a post last night, Ellen Miller explained what real lobbying reform would look like, “Sunlight believes strongly that such disclosures should be made electronically, published promptly and maintained online in a downloadable, searchable, sortable format. We believe that disclosure should include all legislation and regulations discussed and all requests for specific services or government funding. Legislative contacts should be reported within 24 hours of any meeting. In addition, the requirement that contributions by registered lobbyists be reported semiannually should be amended to require contributions be reported within 24 hours of being made.”

First, the President will call for the establishment of a single Congress-wide database so that all of us can track earmarks. A state-of-the-art, user-friendly online database, one that allows users to search, sort, and download machine-readable data, will spur more citizen interest and involvement  — and accountability — in federal budgetary questions.

Sunlight has long advocated transparency to ensure that earmarks reflect the public interest. There is a long history of members abusing earmarks, requesting funding to build bridges to nowhere and to reward political allies, family members and even for personal enrichment. These abuses were most prevalent when there was little transparency in the process. Until 2007, members did not disclose which earmarks they requested, recipients were not named and individual earmarks were scattered throughout a dozen or more congressional committee documents that totaled hundreds of pages.

While the last two Congresses have improved earmark disclosure, it’s still impossible for a citizen to find, in a single place, all the relevant information about the projects their elected lawmakers request before votes are taken on them. What the President is requesting — a centralized database with information posted before final decisions are made — is a much-needed change.

Second, the President is calling for more complete disclosure by lobbyists when  they are lobbying the White House or Congress. Under his plan, each contact would be reported, presumably with enough specificity to be meaningful.  Sunlight believes strongly that such disclosures should be made electronically, published promptly and maintained online in a downloadable, searchable, sortable format. We believe that disclosure should include all legislation and regulations discussed and all requests for specific services or government funding. Legislative contacts should be reported within 24 hours of any meeting. In addition, the requirement that contributions by registered lobbyists be reported semiannually should be amended to require contributions be reported within 24 hours of being made.

And third, the President calls for fixes to the campaign finance system in the wake of the Citizens United Supreme Court decision. We believe that this decision certainly calls for an immediate update to the entire campaign finance disclosure law regime — covering everything from who has to disclose, what is required to be disclosed, how often, and in what form – whether the spending comes directly from corporations’ or unions’ treasuries, from lobbyists, political parties or the candidates themselves. Clearly, now more than ever, our entire system of public disclosure of election-related contributions and expenditures needs to be upgraded to keep pace with the influences it is designed to track. And with the technical capacity we now have in this 24/7 world, this means that disclosures must be filed online, in real time.

We applaud the President for making these new initiatives and stand ready to consult with Congress and the administration to find the best technical means to accomplish these goals.

Excerpts from the Speech below:

Rather than fight the same tired battles that have dominated Washington for decades, it’s time for something new. Let’s try common sense. Let’s invest in our people without leaving them a mountain of debt. Let’s meet our responsibility to the people who sent us here.

To do that, we have to recognize that we face more than a deficit of dollars right now. We face a deficit of trust – deep and corrosive doubts about how Washington works that have been growing for years. To close that credibility gap we must take action on both ends of Pennsylvania Avenue to end the outsized influence of lobbyists; to do our work openly; and to give our people the government they deserve.

That’s what I came to Washington to do. That’s why – for the first time in history – my administration posts our White House visitors online. And that’s why we’ve excluded lobbyists from policy-making jobs or seats on federal boards and commissions.

But we cannot stop there. It’s time to require lobbyists to disclose each contact they make on behalf of a client with my Administration or Congress. And it’s time to put strict limits on the contributions that lobbyists give to candidates for federal office. Last week, the Supreme Court reversed a century of law to open the floodgates for special interests – including foreign companies – to spend without limit in our elections. Well I don’t think American elections should be bankrolled by America’s most powerful interests, and worse, by foreign entities. They should be decided by the American people, and that’s why I’m urging Democrats and Republicans to pass a bill that helps to right this wrong.

I’m also calling on Congress to continue down the path of earmark reform. You have trimmed some of this spending and embraced some meaningful change. But restoring the public trust demands more. For example, some members of Congress post some earmark requests online. Tonight, I’m calling on Congress to publish all earmark requests on a single Web site before there’s a vote so that the American people can see how their money is being spent.

Forgive my enthusiasm for this new app, but it really is something special and elegant. Forget the fact that the platform will be expanded and new data sources will be added and the app will be expanded. I know that I am channeling my inner Don Draper here when I say that this new app brings me home again, and by home, I mean the Longworth House Office Building.

The Real Time Congress application for iPhone will keep journalists, Hill staffers, bloggers and interested citizens up to date on what is happening in Congress, in real-time. Its ease of use and sleek design promise that end users will continue to go back to the app for unfiltered information on Congress so they can make their own informed decisions on what is happening in the Capitol.

Our goal at the Sunlight Foundation is to change the way that citizens collect information about their government, and then help them to use that information to change the way they interact with their government. This new app shows how powerful new programs and smart phones can accomplish that goal. I’m just a little jealous of my former colleagues on the hill—I kind of wish I had this when I was working over there.

We’re pretty proud of the app and it’s free to you as the user. It is worth noting, however, that it wasn’t free for us to create. It did take weeks of development, and so any contribution toward this application and all the others we hope to create in the future on your behalf is greatly appreciated.

Sen. Lisa Murkowski (R-Alaska) is likely to postpone offering an amendment (pdf) next week that would bar the Environmental Protection Agency from regulating carbon dioxide as a pollutant under the Clean Air Act, according to sources familiar with the matter.

…

The maneuvering comes as The Washington Post has confirmed that two Washington lobbyists, Jeffrey R. Holmstead and Roger R. Martella, Jr., helped craft the original amendment Murkowski planned to offer on the floor last fall. Both Holmstead, who heads the Environmental Strategies Group and Bracewell & Guiliani, and Martella, a partner at Sidley Austin LLP, held senior posts at EPA under the Bush administration and represents multiple clients with an interest in climate legislation pending before Congress.

As reported in McClatchy, the lobbyists are very honest about the whole thing:

“This is what lawyers in Washington do every day of the week, is to take a look,” Holmstead said. “It happens all the time on almost every piece of legislation. Before language is introduced, it is almost always shared with people on all sides of the issue.”

All the more reason for even more transparency in the interaction of lobbyists with our elected officials.

In a call to arms, House Republican leaders met with more than 100 lobbyists at the Capitol Visitors Center on Tuesday afternoon to try to fight back against financial regulatory overhaul legislation.

…

“The message was [House Financial Services Chairman Barney] Frank and the Democratic majority are ruining America, ruining capitalism, and stand up for yourselves,” said a lobbyist who attended the meeting. “They said, ‘Look, you all oppose this bill, but only a few of you have come out publicly.’”

Does anyone on Capitol Hill have any interest in releasing these types of visitor logs? Over 100 lobbyists go to meet with House Republicans. House Republicans number one-hundred ninety-eight. Not all of them were likely in this meeting, so in all likelihood we had a 1:1 or greater ratio of lobbyists to lawmakers. Who knows who these lobbyists are?

Of course, this doesn’t just apply to this particular meeting between Republicans and their allies, but also to Democratic lawmakers and their lobbyist sit-downs. The White House has a policy of releasing their visitor logs to the public. Congress should consider letting the public know what lobbyists and industry executives they are sitting down with when they discuss legislation.

You and I can’t hire a the former chief of staff to Senate Finance Committee chairman Max Baucus, but America’s Health Insurance Plans (AHIP) can. Nor can we hire Sen. Blanche Lincoln’s former chief of staff, but a dozen health care companies can. These people have connections that worth more than gold in Washington. They have the ears of the players in Washington.

Roll Call did some more reporting on this and brought us some crucial information on these lobbyists. In particular, I’d like to point to one relationship that I’ve written about more than once. That’s Sen. Blanche Lincoln’s former chief of staff Kelly Bingel. Here’s a visualization that we created showing Lincoln’s connection to Bingel. And here’s what Roll Call has to say:

In the case of key fence-sitter Sen. Blanche Lincoln (D-Ark.), Mehlman Vogel Castagnetti lobbyist Kelly Bingel is said to have the ear of her former boss. Bingel declined to be interviewed for this article, but a former colleague called her “first on the list” of the Senator’s callbacks.

…

“She’s Sen. Lincoln’s alter ego,” a former colleague said.

Organizations with a stake in legislation know that the best way to get the attention of lawmakers is to poach their most connected, most knowledgable staffers and hire them as lobbyists. The ordinary constituent can’t call up a senator and lobby them on a policy issue, but their close buddy and former employee can. Just look at this quote from the Roll Call article:

“It is helpful. We have lines of communication open,” a lobbyist and former Senate Democratic staffer said. “We have access to lay out our argument.”

Without that access you can’t get anything done.

(Most of our coverage of health care lobbyists and the revolving door can be found here.)

As documented in this post from two days ago, Sen. Nelson’s former legislative director now lobbies for three top health insurers: Blue Cross Blue Shield, Aetna and UnitedHealth Group. Sen. Lincoln’s former top health adviser Elizabeth Barnett lobbies for the same three health insurers. Kelly Bingel, Sen. Lincoln’s former chief of staff, lobbies for AHIP. Since 2005, Blue Cross Blue Shield has contributed over $80,000 to Sen. Lincoln and over $65,000 to Sen. Nelson.

Blue Cross Blue Shield is the largest provider of health insurance in both senator’s states. In Arkansas, Blue Cross holds a 75% market share and UnitedHealth Group is second with 6% market share. Blue Cross’ market share in Nebraska is 44% and UnitedHealth Group has a 25% market share. In both states, the removal of the anti-trust exemption could cause serious loss of market share for these companies.

The exclusion of the provision to remove the exemption would be a big win for these former staffers turned lobbyists. Not only did they get what their clients wanted, but the utility of their connections has been publicly touted.

The provision to remove the health insurer anti-trust exemption was included in the House bill and supported by President Barack Obama. It was used by the House and the White House as a stick to keep the health insurance industry from waging a public campaign of opposition. When the industry finally decided to publicly oppose the bill, the provision was included in the final House legislation.

[I]n the first six months of this year alone, drug and biotech companies and their trade associations spent more than $110 million — that’s about $609,000 a day — to influence lawmakers, according to figures compiled by the nonpartisan watchdog group Center for Responsive Politics. The drug industry’s legion of registered lobbyists numbers 1,228, or 2.3 for every member of Congress. And its campaign contributions to current members of Waxman’s committee have totaled $2.6 million over the past three years.

The return on that investment has been considerable, both in the House and in the Senate. “We’ve done very well,” says lobbyist Jim Greenwood, a former Republican Congressman from Pennsylvania who was a member of the Energy and Commerce Committee and now heads the Biotechnology Industry Organization (BIO). “We carried a majority of the Democrats and a majority of the Republicans in each of the committees, and by very clear margins.”

Despite promises to reign in lobbyists, Congress and the White House have done little to affect the actual situation on the ground. The Obama administration has laid the ground work for what could be a promising new system for lobbying disclosure in their limited lurches at the lobbyist complex in Washington — requiring disclosure of lobbyist contacts for bailout and stimulus funds. The current lobbyist disclosure system, however, does not seek to help the public or affect K Street, but instead is aimed at providing lawmakers with an up-to-date list of the people who keep calling their offices. Earlier this year, I wrote about the need for lobbyist contact disclosure. Here are some key graphs from that post to think about when you’re reading the Time article on pharmaceutical lobbying:

Debate over previous lobbying regulation bills (the Federal Regulation of Lobbying Act of 1946, the Lobbying Disclosure Act of 1995, and the Honest Leadership and Open Government Act of 2007) acknowledged that the disclosure by lobbyists is not only due to the potential for corrupting activity, but because they serve an important role and their existence needs to be revealed, not only to the public, but for lawmakers and officials to better understand with whom they are meeting. In fact, the general thrust of the debate during consideration of the Lobbying Disclosure Act of 1995 surrounded the need for lawmakers to be informed of who they are meeting and discussing policy. While this has served the legislative need to know the bias of a caller, it has not served the public interest nor has it helped the factions and interests that hire lobbyists to better police each other.

…The reason why the disclosure of contacts is important is not because we are worried that lobbyists are engaging in a quid-pro-quo but because of associational bias. In her legal essay, St. John’s University law professor Anita Krishnakumar explains that, “…[T]he public perceives that lobbyists receive special face time with elected officials. Irrespective of where that face time occurs — in scheduled meetings, on a train ride, over a game of power, or on the golf course — it creates opportunities for lobbyists to persuade elected officials of their clients’ positions, opportunities that ordinary citizens do not have. In other words, the public’s concern is not just that elected officials will engage in blatant vote-selling to lobbyists, but, more subtly, that they will be partial to the causes of lobbyists’ clients because they spend a lot of time in lobbyists’ company.”

…

The disclosure of lobbying contacts provides not only the public with a better view of which interests and factions are trying to influence outcomes, but it also provides a chance for those same interests and factions to view the actions of their opposition. If union officials are putting a full court press over the Employee Free Choice Act, business groups will be able to see which lawmakers they are targeting and can prepare a better response. Groups can help educate the public on which lawmakers are more supportive of their causes, or if they are in opposition. And some lawmakers, exposed by the sunlight, may find it in their interest to meet with more groups to not only provide a more bipartisan public record, but to also gain insight from a more diverse group of interests.

…

The need for a better system of lobbying disclosure, that increases registration and disclosure, is necessary to provide the public, interests and lawmakers with the information that actually matters and to provide the professional legitimacy that the lobbying industry needs.